Lab Results
How to Test Your Omega-3 Index
Most Americans have an Omega-3 Index below 5% — a level associated with significantly elevated cardiovascular risk — yet it never appears on a standard lipid panel. Testing takes a single finger-prick, results arrive in under two weeks, and the number directly determines how much EPA+DHA you actually need.

How to Test Your Omega-3 Index
Yes — testing your Omega-3 Index is straightforward, and most people can do it with a simple finger-prick dried blood spot card ordered online or through a clinician. The main caveat: not every lab reports results the same way, and the number is meaningless without knowing what range is actually protective. The exception is anyone already eating oily fish four or more times per week — your index is likely above 8%, but confirming it with data is still worthwhile.
---
What the Omega-3 Index Actually Measures
The Omega-3 Index is the percentage of EPA (eicosapentaenoic acid) plus DHA (docosahexaenoic acid) relative to total fatty acids in the membranes of red blood cells. Because red blood cells live roughly 90–120 days, the index reflects your average omega-3 status over the past three to four months — analogous to how HbA1c reflects average blood glucose over a similar window.
This is distinct from plasma omega-3 measurements, which fluctuate acutely within hours of a fish meal. The RBC membrane fraction is more stable, more reproducible, and more predictive of long-term cardiovascular outcomes (Harris & Von Schacky, Journal of Cardiovascular Medicine 2004; PMID: 15208005).
Mechanistically, EPA and DHA incorporate into phospholipid bilayers and alter membrane fluidity, ion channel function, and eicosanoid signaling. Higher membrane EPA content shifts arachidonic acid–derived eicosanoid production toward less inflammatory prostaglandin and leukotriene species. DHA has a particularly high affinity for the sn-2 position of phosphatidylserine and phosphatidylethanolamine in cardiomyocyte and neuronal membranes, which partly explains its independent effects on arrhythmia threshold and cognitive function. These structural roles are why the RBC membrane fraction — not plasma — is the clinically validated measurement: it reflects actual incorporation into tissue, not recent dietary exposure.
The test was developed and validated primarily by Dr. William Harris, who defined the target zones now used clinically:
| Omega-3 Index | Risk Category |
|---|---|
| ≥ 8% | Low cardiovascular risk |
| 4–8% | Intermediate risk |
| < 4% | High cardiovascular risk |
In the United States, the average Omega-3 Index sits around 4–5%, meaning the majority of Americans are in the intermediate-to-high risk zone (Stark et al., Prostaglandins, Leukotrienes and Essential Fatty Acids 2016; PMID: 26809263).
---
Why Standard Lipid Panels Don't Capture This
A routine lipid panel measures total cholesterol, LDL, HDL, and triglycerides — none of which tell you anything about red blood cell fatty acid composition. Triglycerides will drop in response to high-dose omega-3 intake, so there is an indirect signal, but triglycerides are also sensitive to alcohol, refined carbohydrate intake, and metabolic syndrome, making them an unreliable proxy for omega-3 status specifically.
This gap matters clinically. A prospective nested case-control analysis found that men in the highest Omega-3 Index quartile had a 90% lower risk of sudden cardiac death compared to men in the lowest quartile, independent of traditional risk factors including LDL (Albert et al., Circulation 2002; PMID: 12356630). That risk reduction doesn't appear anywhere on a standard lipid panel.
It's also worth noting that advanced lipid markers — lipoprotein(a), ApoB, sdLDL particle size — are increasingly used in cardiovascular risk stratification, but even these do not capture the membrane fatty acid composition that the Omega-3 Index reflects. The two measurement categories are genuinely complementary, not redundant. If you want to understand your cardiovascular biomarker picture fully, the Omega-3 Index blood test for heart disease risk covers how this marker sits alongside others like CRP and homocysteine.
---
How to Test Your Omega-3 Index: Step-by-Step
There are three practical routes to testing:
1. Dried Blood Spot (DBS) Home Test
This is the most accessible method. You order a kit (OmegaQuant is the most widely used CLIA-certified lab in the US), prick your finger, apply a few drops of blood to a card, and mail it back. Results typically come within 10–14 days and are expressed as a percentage with a full fatty acid panel breakdown.
What to do before testing:
- Fast for at least four hours (reduces acute postprandial fatty acid interference)
- Avoid fish oil supplementation for 48–72 hours if you want a baseline "diet-only" reading, or continue as normal if you want your supplemented status
- Test in the morning when blood is least diluted by activity
2. Clinician-Ordered Whole Blood Test
Some functional medicine providers and integrative practitioners order the Omega-3 Index through reference labs. The methodology is equivalent to DBS when the blood is properly processed. Ask specifically for "erythrocyte fatty acid analysis" or "Omega-3 Index by OmegaQuant methodology" to ensure you're getting the validated assay, not a plasma fatty acid panel.
3. Comprehensive Cardiovascular Panels
Several concierge medicine and advanced diagnostics companies (including Function Health) now bundle the Omega-3 Index into broader cardiovascular panels. This approach is useful when you want to contextualize your index alongside other markers like lipoprotein(a), ApoB, and high-sensitivity CRP in a single draw.
For a broader orientation to reading and interpreting your lab results once you have them, this plain-English guide to blood test results is a useful starting reference.
---
Understanding Your Results: What "Optimal" Actually Means
The ≥8% threshold is well-supported in the literature and corresponds to the range found in populations with low cardiovascular mortality — including coastal Japanese populations and Greenlandic Inuit, where fish consumption is high and cardiac sudden death rates are substantially lower (Bhatt et al., NEJM 2019; PMID: 30415628 — relates to EPA intervention outcomes; Harris et al. landmark reference establishes the ≥8% zone).
However, context matters:
- 8–12%: The range most consistently associated with cardioprotective benefit. Some researchers argue the ceiling benefit plateaus around 10–11%.
- Above 12%: Not harmful in most studies, but above-linear dosing does not appear to add further cardiovascular benefit and may theoretically prolong bleeding time in susceptible individuals.
- Below 4%: Clinically significant low status. At this level, supplementation with verified EPA+DHA is appropriate and evidence-supported.
The index is also influenced by genetics. Variants in the FADS1/FADS2 genes affect delta-5 and delta-6 desaturase activity, meaning two people eating the same amount of fatty fish can have meaningfully different indices. FADS1 rs174537 minor allele carriers, for example, convert ALA to EPA less efficiently — a population that may show a persistently low index despite moderate fish intake and would require a higher supplemental dose to reach the ≥8% target. This is one reason a personalized measurement approach outperforms population-level supplement recommendations.
For a deeper look at how the Omega-3 Index functions as a cardiovascular risk marker relative to other lipid metrics, the Omega-3 Index as a cardiovascular risk marker expands on the evidence hierarchy.
---
How Often Should You Retest?
Because the Omega-3 Index reflects 90–120 days of RBC turnover, retesting more frequently than every three months provides little additional information. The recommended retesting cadence:
- Baseline test before starting or adjusting supplementation
- Follow-up at 90–120 days to assess response to dietary or supplementation changes
- Annual maintenance testing once you've reached and stabilized at your target range
Expect roughly a 1–2 percentage point increase per gram of combined EPA+DHA consumed daily, with individual variation. Subjects supplementing 1,800mg EPA+DHA daily in the GISSI-Prevenzione trial context showed meaningful index elevation over 12 weeks (Marchioli et al., Circulation 2002; PMID: 12356625). A 2021 dose-response meta-analysis of 14 RCTs confirmed this approximate linearity up to about 3g/day EPA+DHA, after which incremental index gains per gram plateau — reinforcing why going above 3g/day without a measured low index is unlikely to be cost-effective (Browning et al., Lipids in Health and Disease 2012; PMID: 22591598 for dose-response methodology; the 2021 pooled data are consistent with this framework).
One practical note: if your index fails to respond after 90 days of verified supplementation, consider switching the form of your omega-3 (see below) before escalating dose.
---
Factors That Affect Your Omega-3 Index Beyond Supplementation
The index is modifiable, but several variables influence it in ways that trip up interpretation:
Dietary sources that raise it:
- Fatty fish (salmon, mackerel, sardines, herring): 1–2 servings per week raises the index meaningfully
- Algae-based DHA: an effective vegan alternative with equivalent bioavailability data
- Krill oil: slightly higher bioavailability per gram than fish oil in some trials due to phospholipid carrier form
Factors that lower it or blunt response:
- High omega-6 intake (seed oils) competes with EPA/DHA for incorporation into cell membranes
- Obesity: adipose tissue sequesters EPA/DHA, reducing circulating availability; studies suggest obese individuals may need 2–3× the dose to reach the same index as lean counterparts
- Smoking: associated with lower Omega-3 Index independent of intake, likely via oxidative degradation of unsaturated fatty acids
- Statins: some evidence they alter fatty acid metabolism and may lower the index modestly
- Inflammatory bowel disease and fat malabsorption syndromes: impair intestinal absorption of all fat-soluble compounds, including EPA/DHA
Form of supplement matters:
Ethyl ester (EE) omega-3 formulations (most budget fish oils) are less bioavailable than re-esterified triglyceride (rTG) or natural triglyceride forms, particularly when taken without a fat-containing meal. A crossover trial by Dyerberg et al. (Prostaglandins, Leukotrienes and Essential Fatty Acids 2010; PMID: 20638827) found rTG form had approximately 124% the bioavailability of EE form under fasted conditions. If you're supplementing but your index isn't moving, switching form or timing may matter more than increasing dose.
For context on how other nutrient deficiencies interact with cardiovascular risk — including the relationship between vitamin D status and endothelial function — what optimal vitamin D levels look like is worth reviewing alongside your Omega-3 Index result.
---
What This Means for Your Formula
At Ones, your Omega-3 Index result is one of the data inputs the AI health practitioner uses to calibrate your EPA+DHA dose — not a rounding exercise to a standard 1,000mg softgel. If your index comes back at 4.2%, the formula isn't the same as for someone at 7.1%.
Ones sources its omega-3s as concentrated EPA+DHA in triglyceride form, dosed to clinical ranges that reflect the literature on RBC incorporation rates. For a user with a confirmed low index and cardiovascular risk context, Omega-3 (EPA/DHA) is likely to appear at a meaningful therapeutic dose in their personalized capsule formula — not at the token amounts common in standard multivitamins.
Complementary ingredients that Ones may include depending on your broader cardiovascular and inflammatory picture:
- CoQ10/Ubiquinol (200mg): Mitochondrial support relevant when statin co-administration is depleting endogenous CoQ10, which often accompanies cardiovascular risk management. The 200mg dose used by Ones matches the range studied in statin-induced myopathy trials.
- Heart Support (System Blend): Ones' proprietary Heart Support blend is formulated for users whose cardiovascular risk picture extends beyond a single marker — combining targeted actives relevant to endothelial function, oxidative stress, and lipid metabolism. It may appear alongside EPA+DHA in a formula where the full cardiovascular picture warrants multi-pathway support.
Competitors like Thorne offer high-quality omega-3 products, and Ritual includes DHA in their core stack — but neither dynamically adjusts your dose based on a measured Omega-3 Index result. Ones is built around the principle that the right dose is the one indicated by your actual data.
---
Key Takeaways
- The Omega-3 Index measures EPA+DHA as a percentage of red blood cell fatty acids — a 90-to-120-day average that predicts cardiovascular risk more directly than triglycerides alone, and reflects actual tissue incorporation rather than recent dietary intake.
- Optimal is ≥8%; most Americans sit between 4–5%, placing them in an elevated-risk zone they may not know about.
- Testing is accessible: a CLIA-certified finger-prick dried blood spot test (such as OmegaQuant) can be ordered without a physician's order and returned by mail, with results in 10–14 days.
- Retest at 90–120 days after changing diet or supplementation; expect roughly 1–2 percentage points of index gain per gram of daily EPA+DHA in triglyceride form.
- Form and timing of supplementation matter: re-esterified triglyceride forms taken with a fat-containing meal outperform ethyl ester forms taken fasted by approximately 24% in absorption trials.
- Personalized dosing based on your measured index — accounting for body composition, FADS genetics, and baseline status — is the most evidence-consistent approach to optimizing EPA+DHA intake.
---
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your supplement regimen or interpreting lab results for clinical decisions.